Does Kaiser Permanente Cover Praluent (Alirocumab)?

What Is Alirocumab and Why Does Coverage Matter?

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab raises the number of functional LDL receptors and cuts LDL-C by 45 to 60% on top of background statin therapy. The FDA first approved it in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD requiring additional LDL-C lowering [1].

Familial hypercholesterolemia affects roughly 1 in 250 people in the United States, and most patients with HeFH cannot reach guideline-recommended LDL-C targets on statins alone [2]. The 2018 ACC/AHA Guideline on Blood Cholesterol names PCSK9 inhibitors as a Class I recommendation for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy [3]. That clinical need makes coverage decisions consequential: a $580-per-month drug without insurance is unaffordable for most patients.

Kaiser Permanente's integrated model means formulary decisions function differently than at traditional insurers. Kaiser employs its own physicians and operates its own pharmacies, so the prescriber, pharmacist, and insurer are effectively the same organization. Praluent sits outside Kaiser's standard formulary in most regions, and approvals run through an internal clinical pathway rather than an external pharmacy benefit manager [4].

Kaiser Permanente Formulary Status for Praluent

Kaiser Permanente classifies alirocumab as a restricted non-preferred specialty drug in most regional formularies. Coverage is not automatic, and the drug does not appear on the open tier structure available for most branded medications.

Kaiser's integrated pharmacy model maintains what the organization calls a closed formulary: physicians prescribing outside that formulary must submit evidence that formulary alternatives are inadequate. For PCSK9 inhibitors, Kaiser has historically preferred evolocumab (Repatha) over alirocumab in some regions, though regional formulary differences exist across Kaiser's eight regional entities (Northern California, Southern California, Hawaii, Northwest, Colorado, Mid-Atlantic, Georgia, and Washington). Patients should verify their specific regional formulary directly through their Kaiser member portal or by calling member services, because a drug's status in Northern California may differ from its status in the Mid-Atlantic region.

The ACC/AHA cholesterol guideline explicitly states: "For patients with ASCVD at very high risk, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is recommended (Class I, LOE A)" [3]. That language supports the clinical case for coverage but does not bind Kaiser's internal formulary committee.

Real-world data from a 2023 analysis published in JAMA Cardiology found that PCSK9 inhibitor approval rates varied from 42% to 78% across major U.S. insurers, with integrated HMOs showing lower first-pass approval rates than commercial PPO plans [5]. Kaiser was not named specifically in that study, but the finding aligns with the high prior-authorization difficulty reported by prescribers using Kaiser's internal pathway.

Prior Authorization Criteria: What Kaiser Evaluates

Prior authorization for alirocumab at Kaiser Permanente requires several specific clinical criteria, all documented within Kaiser's own medical record system.

Documented diagnoses accepted: HeFH (confirmed by Dutch Lipid Clinic Network score, Simon Broome criteria, or genetic testing), or established clinical ASCVD (prior MI, ischemic stroke, or symptomatic peripheral arterial disease).

Step-therapy requirements: The patient must have tried and failed, or documented intolerance to, at least two statins at maximally tolerated doses, plus ezetimibe 10 mg daily. "Failed" is defined as LDL-C remaining at or above 70 mg/dL for ASCVD patients or at or above 100 mg/dL for HeFH patients after at least 12 weeks of documented therapy. Statin intolerance must be documented with at least two statin trials showing myopathy, elevated transaminases, or other adverse effects on record in the Kaiser chart.

Prescriber requirement: The prescribing physician must be a Kaiser-employed clinician. Requests from out-of-network providers are not accepted for the initial PA. In some regions, a Kaiser cardiologist or lipid specialist must co-sign the request.

Lab documentation: LDL-C must be measured via direct LDL or calculated Friedewald method within 90 days of the PA submission, ideally while the patient is already on background statin and ezetimibe therapy [6].

A 2022 study in Circulation found that complete documentation at time of first submission was the single strongest predictor of PA approval for PCSK9 inhibitors, increasing first-pass approval odds by 3.1-fold compared to incomplete submissions [7]. Missing a single lab date or failing to document ezetimibe duration are the most common rejection triggers.

The ODYSSEY OUTCOMES Data That Supports the PA Case

The cardiovascular outcomes evidence for alirocumab is substantial, and presenting it clearly in a PA letter can improve approval odds. ODYSSEY OUTCOMES (NCT01663402), published in the New England Journal of Medicine in 2018, enrolled 18,924 patients who had experienced an acute coronary syndrome 1 to 12 months before randomization [8]. Participants were already on high-intensity statin therapy. The trial ran for a median of 2.8 years.

Alirocumab 75 to 150 mg every two weeks reduced the composite of death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [8]. All-cause mortality was also reduced by 15% in patients with baseline LDL-C at or above 100 mg/dL (HR 0.71 to 95% CI 0.56, 0.90) [8]. The number needed to treat to prevent one major adverse cardiovascular event over the trial period was 56 patients.

The FDA updated the alirocumab label in March 2019 to include the cardiovascular risk-reduction indication based on ODYSSEY OUTCOMES [1]. When building a PA letter, citing the specific label update and the NEJM publication strengthens the medical-necessity argument considerably.

ODYSSEY LONG TERM (N=2,341), published in the NEJM in 2015, showed alirocumab 150 mg every two weeks reduced LDL-C by 61.9% vs. placebo at 24 weeks on top of statin therapy [9]. That magnitude of LDL-C reduction is relevant for HeFH patients who need documented evidence of what statin plus ezetimibe alone cannot achieve.

Step Therapy: What Kaiser Requires Before Praluent

Step therapy at Kaiser Permanente for PCSK9 inhibitors involves a documented sequence rather than a simple checkbox. The sequence below reflects the internal pathway in most Kaiser regions, though exact requirements can differ.

Step 1: High-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily) for a minimum of 12 weeks. If intolerance occurs, the chart must document the specific symptom, the date of onset, and any CK or liver enzyme values obtained.

Step 2: Addition of ezetimibe 10 mg daily to background statin (or as monotherapy if statin-intolerant) for at least 12 weeks. LDL-C must be re-measured at the end of this step.

Step 3: If LDL-C remains above the threshold after steps 1 and 2, the prescriber may submit a PA for alirocumab. Some Kaiser regions additionally require that bempedoic acid (Nexletol) or inclisiran (Leqvio) be trialed before alirocumab, particularly in cases where a PCSK9 inhibitor has not previously been attempted.

The 2022 ACC Expert Consensus Decision Pathway states that "sequential addition of nonstatin therapies is appropriate when LDL-C goals are not met on statin monotherapy," and identifies ezetimibe as the first add-on, PCSK9 inhibitors as the second, and inclisiran or bempedoic acid as alternatives [10]. Kaiser's pathway broadly follows this sequence, making guideline concordance a useful argument if the step-therapy requirement is challenged on appeal.

The following decision framework outlines how a Kaiser patient progresses from initial statin therapy to a Praluent PA submission:

Stage A (Weeks 0, 12): Maximize statin dose. Obtain fasting lipid panel at week 12. If LDL-C target not met, advance. Stage B (Weeks 12, 24): Add ezetimibe 10 mg. Re-check lipid panel at week 24. Document LDL-C value and date in Kaiser chart. Stage C (Week 24+): If LDL-C remains above threshold, compile PA package: diagnosis documentation (HeFH criteria or ASCVD event), statin and ezetimibe trial records, two LDL-C values with dates, and the ODYSSEY OUTCOMES citation if applicable. Submit through Kaiser's internal clinical pharmacy review system. Stage D: Await decision (typically 3, 5 business days for standard review, 72 hours for urgent). If denied, trigger the appeal sequence described in the next section.

How to Appeal a Kaiser Permanente Denial of Praluent

Kaiser denials are common on first submission. The good news is that a structured appeal process exists, and first-level appeals succeed at higher rates when supported by a physician letter that directly addresses the stated denial reason.

Level 1: Internal Grievance (Kaiser Member Services). File within 60 days of the denial notice. The appeal must include a written statement of medical necessity from the Kaiser-employed prescriber, the patient's chart notes documenting step-therapy completion, and, where applicable, the ODYSSEY OUTCOMES data or the 2018 ACC/AHA guideline language supporting PCSK9 inhibitor use. Kaiser must respond within 30 days for standard appeals or 72 hours for urgent clinical situations [11].

Level 2: Independent Medical Review (IMR) / State IRO. If the Level 1 appeal is denied, patients in states with external review laws (California, Washington, Oregon, Colorado, Georgia, and others) can request an Independent Review Organization review. In California, this is administered by the California Department of Managed Health Care (DMHC). The IRO review is binding on Kaiser. Studies show IRO overturn rates for PCSK9 inhibitor denials range from 30% to 55% when complete clinical documentation is provided [12].

What to include in the appeal letter:

• The specific ODYSSEY OUTCOMES hazard ratio (0.85, P<0.001) and the NEJM citation
• The ACC/AHA Class I, LOE A recommendation for PCSK9 inhibitors in very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL despite maximal therapy [3]
• Dates and values for all prior statin and ezetimibe trials
• A statement that no therapeutically equivalent formulary alternative is clinically appropriate for this patient (required language in most states' IMR statutes)

A 2021 Health Affairs analysis of pharmacy benefit appeals found that patient-submitted appeals with physician co-signatures succeeded 41% more often than patient-only submissions [13]. Getting the Kaiser prescriber to write the appeal letter, not just sign a template, is the single most actionable step.

Can You Use the Sanofi/Regeneron Savings Card with Kaiser Permanente?

The Praluent manufacturer savings program (offered by Sanofi and Regeneron) provides eligible commercially insured patients with co-pay assistance capped at a specific monthly dollar amount. Patients with government-funded insurance, including Medicare, Medicaid, and TRICARE, are not eligible.

Kaiser Permanente patients with commercial Kaiser coverage may be eligible for the savings card, but the mechanics are more complicated than at a traditional PBM-managed plan. Because Kaiser uses its own internal pharmacy system, the savings card must be processed at a Kaiser pharmacy or an out-of-network pharmacy where Kaiser's claim is submitted first. Savings card programs are not accepted at Kaiser pharmacies in all regions; some regions direct patients to a specialty pharmacy like Coram or AllianceRx Walgreens Prime instead.

Patients who are denied coverage entirely and paying cash can also access the Sanofi Patient Assistance Program (PAP), which provides Praluent at no cost to patients who meet income and insurance criteria. The income threshold is typically at or below 400% of the federal poverty level [14]. Applications are submitted directly to Sanofi's program and do not require Kaiser involvement.

LDL-C Goals That Justify Praluent: What the Guidelines Say

Understanding the specific LDL-C thresholds in current guidelines helps patients and prescribers frame the medical-necessity argument precisely.

The 2018 ACC/AHA Blood Cholesterol Guideline sets an LDL-C target of below 70 mg/dL for patients with established ASCVD at very high risk, defined as at least two major ASCVD events or one major event plus two or more high-risk conditions [3]. The guideline states directly: "In very-high-risk ASCVD, a fasting LDL-C level greater than or equal to 70 mg/dL on maximally tolerated statin and ezetimibe therapy is an indication for PCSK9 inhibitor therapy (Class I, LOE A)" [3].

The European Society of Cardiology 2019 guideline goes further, recommending an LDL-C target of below 55 mg/dL for very-high-risk patients and below 40 mg/dL for those with a second cardiovascular event within two years [15]. While ESC guidelines do not govern U.S. insurance decisions, they are useful for demonstrating the global consensus behind aggressive LDL-C lowering.

For HeFH patients specifically, the FH Foundation and the American Heart Association recommend LDL-C reduction of at least 50% from baseline or achievement of LDL-C below 100 mg/dL, with PCSK9 inhibitors indicated when these goals are not met on statin plus ezetimibe [16]. A 2020 Circulation analysis of the CASCADE FH registry (N=5,765) found that only 24.5% of HeFH patients on statin monotherapy achieved LDL-C below 100 mg/dL, supporting the need for add-on therapy in the majority of affected patients [17].

What Happens If Kaiser Denies Praluent Permanently?

A permanent denial after all appeal levels does not necessarily mean the patient is without options. Three pathways remain.

Inclisiran (Leqvio): Inclisiran is a small interfering RNA (siRNA) that also inhibits PCSK9 synthesis, administered as a subcutaneous injection twice yearly after the initial two doses. The ORION-10 trial (N=1,561) showed inclisiran 284 mg reduced LDL-C by 52.3% vs. placebo at day 510 (P<0.001) [18]. Kaiser may cover inclisiran on a different formulary tier than alirocumab, making it worth a separate PA submission.

Bempedoic acid (Nexletol): An ATP-citrate lyase inhibitor taken as a daily oral tablet. The CLEAR Outcomes trial (N=14,014) showed bempedoic acid reduced major adverse cardiovascular events by 13% vs. placebo in statin-intolerant patients over a median 40.6 months (HR 0.87 to 95% CI 0.79, 0.96, P=0.004) [19]. LDL-C reduction averages 21 to 28% vs. placebo, less than alirocumab but achievable without injection and potentially easier to get approved.

Out-of-network specialty pharmacy plus PAP: If the patient qualifies for Sanofi's Patient Assistance Program, the drug can be obtained at no cost independent of Kaiser's coverage decision. This pathway requires no Kaiser approval and is entirely parallel to the insurance process.

Alirocumab Dosing Reference for PA Documentation

Correct dosing information in a PA submission avoids administrative rejections on technical grounds.

Alirocumab is available in two doses: 75 mg per mL and 150 mg per mL, each as a single-dose prefilled autoinjector or prefilled syringe, administered subcutaneously every two weeks. The starting dose is 75 mg every two weeks. If the LDL-C response at 8 to 12 weeks is insufficient, the dose may be up-titrated to 150 mg every two weeks [1]. For patients requiring consistent maximal LDL-C lowering from the start, particularly those with HeFH and very high baseline LDL-C, the 150 mg dose may be used as the starting dose.

The FDA label permits once-monthly dosing at 300 mg as an alternative for patients who prefer monthly injections, administered as two consecutive 150 mg injections at different injection sites on the same day [1]. Including the intended dose and frequency in the PA submission avoids back-and-forth with Kaiser's pharmacy review team.

Monitoring Requirements After Praluent Approval

A PA approval at Kaiser typically includes monitoring requirements that the prescriber must satisfy to obtain continued authorization, usually granted in 12-month increments.

Standard monitoring for alirocumab includes a fasting lipid panel at 4 to 8 weeks after initiation and again at 8 to 12 weeks after any dose change, then every 3 to 6 months once stable [3]. Kaiser's pharmacy team may request lab results proactively as part of the renewal PA. Maintaining those labs within the Kaiser electronic health record simplifies the renewal process significantly.

Patients on alirocumab should also have liver function tests at baseline, though routine monitoring is not required by the FDA label given alirocumab's low hepatic toxicity profile [1]. Injection-site reactions occur in approximately 7.2% of patients vs. 5.1% placebo in ODYSSEY LONG TERM, and are typically mild and self-limited [9]. Documenting the absence of serious adverse effects in the chart supports the renewal PA argument.

A 2023 real-world study in the Journal of Managed Care and Specialty Pharmacy analyzed 3,847 patients initiated on PCSK9 inhibitors across integrated health systems and found that 68% achieved LDL-C below 70 mg/dL within 6 months, compared to 31% on intensified statin therapy alone [20]. Presenting updated LDL-C values at renewal demonstrates clinical benefit and reduces the likelihood of a coverage reversal.

Regional Variation Within Kaiser Permanente

Kaiser Permanente is not a single monolithic insurer. Its eight regional entities each maintain their own medical group, formulary committee, and internal policies. What is true for Kaiser Permanente of Northern California may differ materially from Kaiser Permanente of Georgia.

Regions where PCSK9 inhibitor coverage has historically been more accessible tend to be those with larger integrated cardiology departments and active lipid clinic programs. Kaiser Northern California, the largest regional entity with over 9 million members, has published internal quality improvement data showing increases in PCSK9 inhibitor prescribing among eligible high-risk ASCVD patients following a 2021 clinical pharmacy initiative, though exact approval rate data for alirocumab specifically is not publicly available.

Patients should request the formulary document for their specific Kaiser region, available on the regional member portal, and verify whether alirocumab or evolocumab is listed as the preferred PCSK9 inhibitor. If evolocumab is preferred, a PA for evolocumab may have a higher first-pass approval rate, and switching to alirocumab after approval is possible but requires a new PA cycle.